Obliteration of mastoid cavities: 30 years of experience with recommendations for surgical strategy

Abstract

The obliteration of mastoid cavities is an appropriate intervention to sustainably improve patients' quality of life. After 30 years, 843 cases of mastoid obliteration were analyzed from the pool of data resulting from 16,000 surgical procedures on the ear. The materials used by the authors included cartilage/bone, Palva flaps, and bone pâté; as well as alloplastic material such as hydroxyapatite (HA) and bioactive glass granules (BAG S53P4) from BonAlive® (BonAlive Biomaterials Ltd., Turku, Finland). Pathological findings included rejection with inflammation, granulation of the auditory canal reconstruction, unclear retraction pockets, as well as shrinkage and cicatricial contraction. The follow-up interval was at least 4 months, with an average of 33 months (standard deviation ± 27.8 months). Use of HA was discontinued after 18 cases, because rejection and retraction occurred in 33% of patients. The same applied for bone pâté after 33 cases, with a pathological finding in 21%. The Palva flaps (145 cases) showed pathological findings in 21% of cases, primarily in the form of shrinkage (7%) and retractions (10%). Cartilage/bone pieces (516 cases) and BAG S53P4 (133 cases) only showed abnormal postoperative findings in 8% and 3%, respectively. It is recommended to focus particularly on auditory canal and canal entrance expansion during mastoid obliteration surgery. When using the bioactive glass granules, postoperative use of a mini-drain for 1-2 days is beneficial, in order to avoid accumulation of seroma fluid in the mastoid. In our experience, a combination of BAG S53P4 and cartilage as cover is a suitable material for cavity obliteration.